INTRODUCTION
In 1925, Cooley and Lee first described a form of anemia that occurred early in life and was associated with spleenomegaly and bone changes. They named it as Cooley's anemia. 1 They described it as a congenital hemolytic anemia syndrome showing microcytic hypochromic anemia of varying severity with welldefined features such as anemia, icterus, characteristic facial appearance, skeletal changes, splenomegaly, familial aspects and appearance of large number of normoblasts in peripheral blood film. Similar descriptions were published shortly afterward by Greppi and Michelli. 2 There are more than 200 mutations in β-thalassemia most of which are rare. Hemoglobin is a conjugated protein of molecular wt. 64000 KD and consisting of an Iron Thalassemias are most common single gene disorder in world and represent a major health burden. About 15 million have clinically apparent thalassemic disorder. [4] [5] [6] Individuals with thalassemia major have a quantitative defect in beta chain production and thus decreased levels of HbA. Such patients have severe anemia and hepatospleenomegaly and usually come to medical attention within the first two years of life. Without treatment, affected children suffer from severe failure to thrive and have shortened life expectancy.
Mainstay of treatment of severe β-thalassemia is regular blood transfusions. Blood transfusion is mandatory for children with thalassemia major and thalassemia intermedia who cannot maintain Hb above 7gm/dl, or those who show evidence of growth retardation and hyperspleenism.
Complications secondary to transfusional iron overload can be prevented by adequate iron chelation with desferrioxamine, deferiprone and deferasirox over last 3 decades development of regular blood transfusion therapy and iron chelation has dramatically improved the quality of life. Hydroxyurea is an oral agent widely used in the treatment of myeloproliferative disorders with a good safety profile. Hydroxyurea was first used in a number of small scale non-randomized clinical studies that confirmed its HbF inducing activity in sickle cell disease. Present study was to evaluate the role of Hydroxyurea in β-thalassemia major patients in already resource constrained settings.
METHODS
This was a hospital based interventional study, and was conducted over a period of 10 months at thalassemia clinic in post graduate department of pediatrics at govt. medical college and hospital, Jammu. Patients of β-thalassemia major attending the clinic, which fulfilled the inclusion criteria were selected as cases as well as controls. An informed written consent was taken from the parents/guardian of the patients to ensure compliance and regular follow up.
Inclusion criteria
 Diagnosed cases of β-thalassemia major.  Patient who could not be followed up.
Therapy protocol
Cases: Seventeen patients meeting all the inclusion criteria were administerd hydoxyurea in a dose of 15 mg/kg/day in a single dose. Folic acid 5 mg once daily was given during whole therapy. During the study patients were followed up after every thirty days Controls: Cases selected for the study also acted as control, and transfusion requirement during last ten months was taken as control.
Detailed history including age at presentation, age at diagnosis, H/O Consanguinity of parents, frequency of blood transfusion required, HIV/HBsAg/HCV status, as well as detailed physical examination and following investigations were done at the time of enrollment at start of therapy and repeated at 3 monthly intervals:
 Liver function tests.
 Renal functional tests.
 HIV and HBsAg and HCV.
 Serum ferritin level by ELISA.
 Serum calcium and phosphorus.
Estimation of blood transfusion levels: Blood transfusion requirements were given to keep Hb above 10 gm/ dl. The need for blood transfusions was assessed at 3 monthly intervals and compared to the blood transfusion requirements in the 10 months prior to intervention.
Estimation of serum ferritin
Serum ferritin is estimated by Chemiluminiscent method done by ADVIA centaur CP ferritin assay. It is a two way sandwich immune assay using direct Chemiluminometric technology which uses constant amounts of two antiferritin antibodies. Serum ferritin levels were measured at 3, 6 and 10 months after starting treatment and compared to baseline serum ferritin levels which acted as control.
Mean, standard deviation and standard error of mean (SEM) were calculated from the data collected.
Results obtained were analyzed statistically by using student's paired T-test and Chi-square test.
RESULTS
A total of 17 patients meeting all the inclusion criteria were selected to receive oral hydroxyurea. The mean age ± SD of the subjects at the time of enrollment was 10.05 ± 2.89 years, while the age at the time of diagnosis was 12.11±11.46 months. The mean weight and height at the time of enrollment were 24.82 ± 8.02 kg and 105.47 ± 11.06 cm respectively. Among 17 cases of thalassemia major there were 8 (47.06%) male cases and 9 (52.94%) female cases. Out of total 17 patients, 1 (5.8%) patient was splenectomised. None of the patient was HIV, HBsAg or HCV positive at enrollment as well as the end of the study. All of the patients were on chelation treatment for a mean duration of 6.8 ± 2.97 years. 15 (88.23%) of the patients were on mono chelation therapy and 2 (11.76%) were on combined chelation therapy. Out of 15 (88.23%) patients on mono chelation therapy 10 (66.66%) patients were on oral deferiprone, 1 (6.66%) on desferrioxamine and 4 (26.66%) were on the new oral chelator deferasirox. Combine therapy consisted on deferiprone and desferrioxamine. Out of 17 thalassemia cases studied, weight and height of 9 and 12 patients respectively were below <3 rd percentile. Weight of 5 and height of 5 patients were between 3 rd to 50 th percentiles. Only 3 patient's weight was more than 50 th percentile. None of the patient has weight or height more than 90th percentile. These findings indicate a high incidence of stunting and wasting among thalassemics. The mean haemoglobin level at the time of enrollment in the study was 7.02 gm/dl, ranged between 6.5 to 9.0 gm/dl. The mean haemoglobin level calculated from the values of pre transfusion haemoglobin in the preceding 10 months to the study was 7.03 gm/dl, ranged between 6.2 to 8.0 gm/dl. At 15 days, 1 month and 2 months no significant increases was observed in the mean haemoglobin levels (P>). At 3 months, the mean haemoglobin level increased to 7.50 gm/dl but this increase was also not statistically significant. The mean Hb level at 6 months was 7.62 gm/dl, haemoglobin increased and it was statistically significant (P<) as compared with the value of 6 months prior to the study. The mean haemoglobin levels at 10 months of study was 7.72 gm/dl, a statistically significant difference was found when this value was compared with the value of mean haemoglobin level at 6 months prior to study (P).
The average number of transfusions before enrollment in the study was 14.93 ± 5.209 while during the study at 6 and 10 months were 7.86 ± 3.46 and 4.20 ± 2.17 respectively. This figure shows a statistically significant decrease in the number of transfusion during the hydroxyurea therapy at 10 months (P <0.05). There was also a statistically significant increase in the interval between the transfusions during the study from a mean of 22.93 ± 7.10 days to 27.93 ± 8.81 days at 6 months and 29.33 ± 11.15 days at 10 months. The mean value of serum ferritin in our patients at the time of enrollment in the study was found 4502.04 ± 1662.65 ng/dl. The ferritin level observed in 10 months prior to the study from the records was 2409.33±1854.09. Over 10 months of study period serum ferritin levels decreased significantly in all cases 3 rd months onwards. The observed mean were 3782.73 ± 1901.04 ng/dl at 3 months of the therapy. The observed mean were 3782.73 ± 1901.04, 2902.06 ± 1784.40, 2416.4 ± 1258.93 at 3, 6 and 10 months of therapy respectively. Close scrutiny of above data shows that serum ferritin levels significantly decreased in all patients after 3 months of therapy. 
DISCUSSION

Epidemiological profile
A total of 17 patients were selected after applying inclusion and exclusion criteria and taking consent from among the patients attending the thalassemia day care center of govt. medical college, Jammu. The selected patients were comparable with respect to sex 8 (47.06%) male cases and 9 (52.94%) female cases. All the patients were non-reactive for HbsAg, HCV and HIV at the beginning of the study and none converted serologically positive for the above mentioned diseases at the end of the study. Among the 17 thalassemia cases studied, weight of 9 and height of 12 patients were respectively below 3 rd centile whereas Weight and height of 5 patients were between 3 rd to 50 th centile for CDC normogram for their age and sex indicating a high incidence of growth retardation among thalassemics. This finding in our study is supported by a longitudinal study done by Saxena et al. on 90 thalassemic patients. 7 The dose of hydroxyurea used in the study period was 15 mg/kg/day as a single oral dose.this was similar to dose of hydroxyurea used in previous studies viz Zamani F et al. with mean dose of hydroxyurea was 10 mg/kg/day (8-15 mg/kg). 8 The mean follow up time was 60 months, Kosaryan M et al. with dose of hydroxyurea was 15.5 ± 6.4 mg/kg/day and duration was 5.2 ± 2 years (ranging 0.5-9 years) and Fucharosen S et al. who administered HU (10-20 mg/kg/day) for 5 months in 13 patients with beta thalassemia major/HbE.
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Change in hemoglobin level
In our study the mean hemoglobin level at the time of enrollment was 7.02 gm/dl, (range 6.5-9.0 gm/dl). The mean hemoglobin level calculated from the values of pretransfusion hemoglobin in the preceding 10 months to the study (control value) was 7.03 gm/dl (range 6.2-8.0 gm/dl). The mean hemoglobin level at 3, 6 months and 10 months were 7.50, 7.62 and 7.72 gm/dl respectively, hemoglobin increases and a statistically significant increase was found when these values were compared with the control value. Once increased, the rise in hemoglobin was consistent and progressive with increasing duration of HU therapy. Similar findings were reported by Bradai M et al. reported a marked elevation of initial mean Hb levels from 65.0 to 105.0 gm/l (6.5-10.5 gm/dl) in two children with thalassemia intermedia, and from 45.0 ± 9.0 to 79.0 ± 8.0 gm/l (4.5 ± 0.9 to 7.9 ± 0.8 gm/dl) in 5 children with thalassemia major. 11 Zamani F et al. also observed 8.2% increases in the mean hemoglobin over 60 months of follow up time. 8 Fucharosen S et al. also observed slight (10%) but statistically significant increase in hemoglobin levels. 10 In another study done by Ansari et al a rise in mean pre transfusion Hb level 7.2g/dl to 8.6 g/dl was observed. 12 Singer ST et al have also reported a mean 1.3g/dl steadystate increase in Hb in 40% of patients, and a milder response (≤1 g/dl) in the others. 
